MediciNova granted two patents for MN-001 asthma treatment

By Lisa Kerner

Erie, Pa., Jan. 5 - MediciNova, Inc. received two patents covering its MN-001 candidate treatment for asthma.

Once granted, the patents will afford the company market exclusivity to 2023.

MediciNova's applications - for which it has now received Notices of Allowance from the U.S. Patent and Trademark Office - cover compositions, uses and manufacturing processes associated with MN-001.

Results from MediciNova's phase 2 clinical trial of MN-001 were positive, indicating that MN-001 improves respiratory function in asthma patients compared to a placebo, the company said.

MN-001 is an orally administered, small molecule inhibitor of inflammatory mechanisms (e.g. phosphodiesterase IV, 5-lipoxygenase, leukotriene receptors) known to be involved in diseases like asthma.

"The issuance of these Notices of Allowance, coupled with the recent positive phase 2 clinical results in asthma patients, illustrates MediciNova's approach and commitment to add significant value to the lead candidates in its development programs and to protect its valuable assets, such as MN-001," stated Yuichi Iwaki, executive chairman and acting chief executive officer of MediciNova, Inc., in a news release.

San Diego-based MediciNova is a specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.